Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. (TWSE:1795) agreed to acquire Teva Pharma (Thailand) Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. for TWD 1.5 billion on June 6, 2024. A cash consideration of TWD 1.5 billion will be paid by Lotus International Pte.

Ltd and Lotus Pharmaceutical Co., Ltd. As part of consideration, TWD 1.5 billion is paid towards common equity of Teva Pharma (Thailand) Co., Ltd. The transaction is approved by acquirer board.